4KNB

C-Met in complex with OSI ligand


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 
    0.288 (Depositor), 0.300 (DCC) 
  • R-Value Work: 
    0.240 (Depositor), 0.250 (DCC) 
  • R-Value Observed: 
    0.241 (Depositor) 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted 1RUClick on this verticalbar to view details

This is version 1.1 of the entry. See complete history


Literature

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.

Steinig, A.G.Li, A.H.Wang, J.Chen, X.Dong, H.Ferraro, C.Jin, M.Kadalbajoo, M.Kleinberg, A.Stolz, K.M.Tavares-Greco, P.A.Wang, T.Albertella, M.R.Peng, Y.Crew, L.Kahler, J.Kan, J.Schulz, R.Cooke, A.Bittner, M.Turton, R.W.Franklin, M.Gokhale, P.Landfair, D.Mantis, C.Workman, J.Wild, R.Pachter, J.Epstein, D.Mulvihill, M.J.

(2013) Bioorg Med Chem Lett 23: 4381-4387

  • DOI: https://doi.org/10.1016/j.bmcl.2013.05.074
  • Primary Citation of Related Structures:  
    4KNB

  • PubMed Abstract: 

    A series of novel 6-aminofuro[3,2-c]pyridines as kinase inhibitors is described, most notably, OSI-296 (6). We discuss our exploration of structure-activity relationships and optimization leading to OSI-296 and disclose its pharmacological activity against cMET and RON in cellular assays. OSI-296 is a potent and selective inhibitor of cMET and RON kinases that shows in vivo efficacy in tumor xenografts models upon oral dosing and is well tolerated.


  • Organizational Affiliation

    OSI Pharmaceuticals, LLC, A Wholly-Owned Subsidiary of Astellas US, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA. arnosteinig@gmail.com


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Hepatocyte growth factor receptor
A, B, C, D
287Homo sapiensMutation(s): 0 
Gene Names: MET
EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P08581 (Homo sapiens)
Explore P08581 
Go to UniProtKB:  P08581
PHAROS:  P08581
GTEx:  ENSG00000105976 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP08581
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
1RU
Query on 1RU

Download Ideal Coordinates CCD File 
E [auth A],
H [auth B],
J [auth C],
K [auth D]
7-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-6-amine
C23 H22 Cl2 F N5 O2
RFKWZWJQRQCLJF-GFCCVEGCSA-N
GBL
Query on GBL

Download Ideal Coordinates CCD File 
F [auth A],
G [auth A],
I [auth B]
GAMMA-BUTYROLACTONE
C4 H6 O2
YEJRWHAVMIAJKC-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
1RU BindingDB:  4KNB IC50: min: 47, max: 410 (nM) from 2 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free:  0.288 (Depositor), 0.300 (DCC) 
  • R-Value Work:  0.240 (Depositor), 0.250 (DCC) 
  • R-Value Observed: 0.241 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 44.713α = 90
b = 85.922β = 91.47
c = 156.469γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XSCALEdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted 1RUClick on this verticalbar to view details

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2014-04-30
    Type: Initial release
  • Version 1.1: 2024-02-28
    Changes: Data collection, Database references, Derived calculations